NCT06806982View on ClinicalTrials.gov

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

July 31, 2027

Conditions

HER2-positive Solid Tumors

Interventions

DRUG

VRN101099

Oral capsules

Trial Locations (1)

2010

RECRUITING

St Vincent's Hospital Sydney, Darlinghurst

All Listed Sponsors

lead

Voronoi, Inc

INDUSTRY